-$0.11 EPS Expected for Collegium Pharmaceutical Inc (COLL) This Quarter
Equities analysts predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will post earnings of ($0.11) per share for the current quarter, Zacks reports. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.06). Collegium Pharmaceutical reported earnings of ($0.45) per share during the same quarter last year, which indicates a positive year over year growth rate of 75.6%. The firm is scheduled to issue its next earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.72) to ($0.49). For the next year, analysts anticipate that the company will post earnings of $0.60 per share, with EPS estimates ranging from $0.00 to $1.20. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.02. The firm had revenue of $73.10 million for the quarter, compared to analysts’ expectations of $72.21 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The company’s quarterly revenue was up 1930.6% compared to the same quarter last year.
A number of large investors have recently added to or reduced their stakes in COLL. Millennium Management LLC grew its stake in Collegium Pharmaceutical by 1,171.8% during the 2nd quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock valued at $8,611,000 after acquiring an additional 332,647 shares in the last quarter. Summit Trail Advisors LLC grew its stake in Collegium Pharmaceutical by 2,221.9% during the 1st quarter. Summit Trail Advisors LLC now owns 332,708 shares of the specialty pharmaceutical company’s stock valued at $333,000 after acquiring an additional 318,379 shares in the last quarter. BlackRock Inc. grew its stake in Collegium Pharmaceutical by 13.8% during the 2nd quarter. BlackRock Inc. now owns 2,252,273 shares of the specialty pharmaceutical company’s stock valued at $53,717,000 after acquiring an additional 272,302 shares in the last quarter. Macquarie Group Ltd. grew its stake in Collegium Pharmaceutical by 9.9% during the 2nd quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock valued at $61,732,000 after acquiring an additional 233,598 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Collegium Pharmaceutical by 78.5% during the 2nd quarter. Northern Trust Corp now owns 526,499 shares of the specialty pharmaceutical company’s stock valued at $12,557,000 after acquiring an additional 231,463 shares in the last quarter. 93.57% of the stock is currently owned by institutional investors.
COLL traded up $0.41 during trading on Friday, reaching $17.08. The company had a trading volume of 638,574 shares, compared to its average volume of 530,798. The stock has a market capitalization of $489.69 million, a P/E ratio of -6.91 and a beta of 0.43. Collegium Pharmaceutical has a 12-month low of $9.01 and a 12-month high of $29.90. The company has a current ratio of 0.82, a quick ratio of 0.78 and a debt-to-equity ratio of 3.94.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Recommended Story: What does RSI mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.